Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors - PubMed (original) (raw)
Clinical Trial
. 2006 Jan 20;24(3):401-6.
doi: 10.1200/JCO.2005.03.6046.
Affiliations
- PMID: 16421420
- DOI: 10.1200/JCO.2005.03.6046
Clinical Trial
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
Matthew H Kulke et al. J Clin Oncol. 2006.
Abstract
Purpose: Standard, intravenous chemotherapy regimens for neuroendocrine tumors have been associated with limited response rates and significant toxicity. We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors.
Patients and methods: Twenty-nine patients were treated with a combination of temozolomide, administered at a dose of 150 mg/m2 for 7 days, every other week, and thalidomide at doses of 50 to 400 mg daily. Patients were followed for evidence of toxicity, biochemical response, radiologic response, and survival.
Results: Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors). The median duration of response was 13.5 months, 1-year survival was 79%, and 2-year survival was 61%. The median administered dose of temozolomide was 150 mg/m(2), and the median administered dose of thalidomide was 100 mg daily. Grade 3-4 toxicities were uncommon, with the exception of grade 3-4 lymphopenia, which developed in 69% of the patient population. Opportunistic infections occurred in three patients (10%) during the time of lymphopenia, and included single cases of Pneumocystis carinii pneumonia, disseminated varicella zoster virus, and herpes simplex virus.
Conclusion: Orally administered temozolomide and thalidomide seems to be an active regimen for the treatment of neuroendocrine tumors. In this 29-patient study, this regimen appeared more active in pancreatic endocrine tumors than in carcinoid tumors.
Similar articles
- Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Chan JA, et al. J Clin Oncol. 2012 Aug 20;30(24):2963-8. doi: 10.1200/JCO.2011.40.3147. Epub 2012 Jul 9. J Clin Oncol. 2012. PMID: 22778320 Free PMC article. Clinical Trial. - Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N, Middleton MR. Danson S, et al. J Clin Oncol. 2003 Jul 1;21(13):2551-7. doi: 10.1200/JCO.2003.10.039. J Clin Oncol. 2003. PMID: 12829675 Clinical Trial. - Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(8):1275-90. doi: 10.2217/fon.14.302. Future Oncol. 2015. PMID: 25832882 Review. - [A case of metastatic pheochromocytoma with remarkable response to combination of cyclophosphamide, vincristine and dacarbazine].
Naoi Y, Tamaki Y, Ooka M, Tsukamoto F, Miyoshi Y, Tanji Y, Taguchi T, Noguchi S. Naoi Y, et al. Gan To Kagaku Ryoho. 2003 Jan;30(1):145-9. Gan To Kagaku Ryoho. 2003. PMID: 12557721 Review. Japanese.
Cited by
- The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012.
Macedo D, Amaral T, Fernandes I, Sousa AR, Costa AL, Távora I, Quintela A, Cortes P, Costa L. Macedo D, et al. ISRN Hepatol. 2013 Feb 14;2013:702167. doi: 10.1155/2013/702167. eCollection 2013. ISRN Hepatol. 2013. PMID: 27335831 Free PMC article. Review. - S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial.
Chi Y, Song L, Liu W, Zhou Y, Miao Y, Fang W, Tan H, Shi S, Jiang H, Xu J, Jia R, Zheng B, Jiang L, Zhao J, Zhang R, Tan H, Wang Y, Chen Q, Yang M, Guo X, Tong Z, Qi Z, Zhao F, Yan X, Zhao H. Chi Y, et al. EClinicalMedicine. 2022 Sep 26;54:101667. doi: 10.1016/j.eclinm.2022.101667. eCollection 2022 Dec. EClinicalMedicine. 2022. PMID: 36188432 Free PMC article. - Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM. Neff LM, et al. Pituitary. 2007;10(1):81-6. doi: 10.1007/s11102-007-0014-1. Pituitary. 2007. PMID: 17285366 - Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.
Poncet G, Faucheron JL, Walter T. Poncet G, et al. World J Gastroenterol. 2010 Apr 14;16(14):1696-706. doi: 10.3748/wjg.v16.i14.1696. World J Gastroenterol. 2010. PMID: 20380000 Free PMC article. Review. - Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines.
Gosain R, Mukherjee S, Yendamuri SS, Iyer R. Gosain R, et al. Cancers (Basel). 2018 Dec 12;10(12):510. doi: 10.3390/cancers10120510. Cancers (Basel). 2018. PMID: 30545054 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials